Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
468,45 €
0,11 %
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 450 €, das unter 468.45 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -3.94%.
